tiprankstipranks
Argent Biopharma (AU:RGT)
ASX:RGT
Holding AU:RGT?
Track your performance easily

Argent Biopharma (RGT) Income Statement

2 Followers

Argent Biopharma Income Statement

Last quarter (Q4 2022), Argent Biopharma's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Argent Biopharma's net income was AU$―. See Argent Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 24Jun 23Jun 22Jun 21Jun 20
Total Revenue
-AU$ 891.08KAU$ 3.39MAU$ 4.74MAU$ 2.96MAU$ 2.08M
Cost of Revenue
-AU$ 687.39KAU$ 1.94MAU$ 2.92MAU$ 1.65MAU$ 1.90M
Gross Profit
-AU$ 203.70KAU$ 1.45MAU$ 1.82MAU$ 1.31MAU$ 174.66K
Operating Expense
-AU$ 18.87MAU$ 17.05MAU$ 16.07MAU$ 13.38MAU$ 11.98M
Operating Income
-AU$ -18.67MAU$ -15.76MAU$ -14.25MAU$ -12.07MAU$ -11.80M
Net Non Operating Interest Income Expense
-AU$ -480.55KAU$ -257.16KAU$ -209.84KAU$ 361.50KAU$ -123.25K
Other Income Expense
-AU$ -784.28KAU$ -5.28MAU$ 1.24MAU$ -3.01MAU$ -6.84M
Pretax Income
-AU$ -17.55MAU$ -21.13MAU$ -20.77MAU$ -15.44MAU$ -18.77M
Tax Provision
--AU$ 2.02K-AU$ -27.28KAU$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-AU$ -17.53MAU$ -20.82MAU$ -20.77MAU$ -15.87MAU$ -19.36M
Basic EPS
-----AU$ -0.01
Diluted EPS
-----AU$ -0.01
Basic Average Shares
-----AU$ 1.38B
Diluted Average Shares
-----AU$ 1.38B
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-AU$ 19.56MAU$ 18.99MAU$ 18.99M--
Net Income From Continuing And Discontinued Operation
-AU$ -17.53MAU$ -20.82MAU$ -20.77MAU$ -15.87MAU$ -19.36M
Normalized Income
-AU$ -13.98MAU$ -12.58MAU$ -20.77MAU$ -15.46MAU$ -13.64M
Interest Expense
-----AU$ 135.58K
EBIT
-AU$ -17.07MAU$ -20.87MAU$ -20.56MAU$ -15.80MAU$ -18.63M
EBITDA
-AU$ -15.77MAU$ -20.12M--AU$ -18.15M
Currency in AUD

Argent Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis